Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kraft Heinz Co (KHC) vs Eli Lilly And Co (LLY) Price & Performance

Kraft Heinz CoTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Kraft Heinz Co vs Eli Lilly And Co — how do they compare? Kraft Heinz Co trades at $25.83 (market cap $30.66B), while Eli Lilly And Co trades at $1,165.57 (market cap $1.02T). The key difference: Eli Lilly And Co is far larger — about 33.3× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (6.19%). Which is the better fit depends on your goals.

KHCLLY
Market Cap
$30.66B$1.02T
Sector
Consumer StaplesHealth
52-Week High
$28.94$1.24K
52-Week Low
$21.21$625.65
Enterprise Value
$47.71B$1.06T
Dividend Yield
6.19%0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kraft Heinz Co

Kraft Heinz (KHC) trades at $26.05, up 0.66% today, with a bullish technical signal and recent earnings beats. The stock shows strong operating cash flow of $4.46B in 2025 but faces profitability challenges with a net income margin of -23.05%. Analysts are mixed, with 57% holding a neutral stance, while the company's reorganization aims to spur growth. The dividend yield remains attractive at approximately 6.4%, supported by solid cash generation.

Outlook: KHC offers value with a low P/B of 0.73 and high dividend, but risks include persistent net losses and high debt. The upcoming Q2 2026 earnings on August 5 will be critical for confirming turnaround progress. Investors should weigh the dividend stability against fundamental weaknesses in a competitive food sector.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Kraft Heinz Co

In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.

Read more on KHC

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY